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Abstract		 Research	on	diseases	such	as	cancer	reveals	that	primary	mechanisms,	which	have	been	the	focus	of	study	by	the	new	mechanists	in	philosophy	of	science,	are	often	subject	to	control	by	other	mechanisms.	Cancer	cells	employ	the	same	primary	mechanisms	as	healthy	cells,	but	control	them	differently.	I	use	cancer	research	to	highlight	just	how	widespread	control	is	in	individual	cells.	To	provide	a	framework	for	understanding	control,	I	reconceptualize	mechanisms	as	imposing	constraints	on	flows	of	free	energy,	with	control	mechanisms	operating	on	flexible	constraints	in	primary	mechanisms.	Control	mechanisms	themselves	often	form	complex,	integrated	networks.			
1.	Introduction		The	new	mechanists	in	philosophy	of	science	emphasize	the	role	of	mechanisms	in	generating	biological	phenomena.	They	have	commonly	construed	mechanisms	as	discrete	entities	that	operate	individually	to	generate	a	given	phenomenon	(e.g.,	the	synthesis	of	proteins).	But	these	primary	mechanisms	are	often	subject	to	control	by	other	mechanisms.	The	activity	of	some	mechanisms	exercising	control	over	other	mechanisms	often	becomes	apparent	in	the	context	of	disease	in	which	changes	in	control	mechanisms	cause	primary	mechanisms	to	behave	in	aberrant	ways.	This	is	especially	true	in	the	case	of	cancer.	Cancer	cells	maintain	themselves	as	living	systems	in	a	radically	transformed	state	not	by	creating	new	primary	mechanisms	but	by	taking	advantage	of	already	existing	primary	mechanisms	and	controlling	them	in	new	ways.1	By	directing	researchers	to	the	control	mechanisms	that	are	altered	in	cancer,	cancer	research	has	highlighted	just	how	abundant	and	complex	these	control	mechanisms	are.	In	this	paper	I	draw	upon	cancer	research	to	develop	the	distinction	between	primary	and	control	mechanisms,	characterize	how	the	two	types	of	
                                                      
1 In	this	paper	I	will	focus	on	the	alterations	within	individual	cancer	cells,	but	it	is	important	to	recognize	that	cancer	is	not	just	a	disease	of	individual	cells	but	ultimately	involves	tissues	and	organs	of	multi-cellular	organisms.	Within	tumors	there	are	complex	intercellular	control	systems	that	regulate	the	behavior	of	individual	cells.	But	much	of	what	is	now	known	about	the	altered	functioning	in	cancer	concerns	control	mechanisms	within	individual	cells.	Focusing	on	intracellular	control	is	sufficient	to	make	the	point	that	understanding	biological	mechanisms	requires	a	focus	not	just	on	their	parts,	operations,	and	organization,	but	on	the	extensive	control	networks	that	operate	on	the	constraints	that	enable	each	mechanism	to	produce	its	phenomenon. 
mechanisms	are	related,	and	to	argue	for	the	importance	of	understanding	control	mechanisms	within	a	network	perspective.		To	understand	the	role	of	mechanisms	performing	control	operations	on	other	mechanisms	requires	expanding	the	characterization	of	mechanisms	as	parts	and	operations	organized	to	generate	a	phenomenon.	In	section	2	I	offer	a	framework	for	understanding	the	components	of	mechanisms	as	constraints,	some	of	which	are	flexible	and	able	to	be	operated	on	and	altered	by	other	mechanisms.	In	section	3,	I	provide	a	characterization	of	cancer	as	manifest	in	the	altered	operations	of	ordinary	cell	mechanisms,	drawing	on	what	Hanahan	and	Weinberg	(2000,	2011)	termed	the	hallmarks	
of	cancer.	In	section	4	I	develop	how	these	hallmarks	stem	from	alterations	in	control	systems	operative	in	cells	that	in	turn	act	on	the	constraints	in	primary	mechanisms.	In	section	5	I	focus	in	greater	detail	on	the	particular	control	systems	affecting	glucose	metabolism	in	cancer	cells.	The	individual	control	pathways	discussed	in	sections	4	and	5	interact	with	each	other	in	numerous	ways.	Thus,	in	section	6	I	turn	to	how	this	points	to	a	need	to	shift	from	a	focus	on	control	pathways	that	are	individually	interpretable	as	mechanisms	to	a	focus	on	control	networks	in	which	multiple	control	mechanisms	are	embedded.			
2.	Rethinking	Biological	Mechanisms:	Constraints	and	Control		The	now	standard	view	of	biological	mechanisms	construes	them	as	consisting	of	entities	or	parts,	each	performing	an	activity	or	operation,	organized	so	as	to	produce	a	phenomenon	(Machamer,	Darden,	and	Craver	2000;	Bechtel	and	Abrahamsen	2005).	On	this	view,	a	biological	mechanism,	much	like	human-made	machines,	is	an	enduring	system	that	awaits	its	start	up	conditions	and	then	carries	out	its	activities	until	it	reaches	its	termination	condition.	The	only	changes	are	the	regular	changes	that	occur	along	the	way	form	start	to	termination	conditions.	In	previous	work	(Bechtel	and	Abrahamsen	2010,	2013),	I	have	emphasized	the	dynamic	character	of	mechanisms—they	are	not	static	systems	awaiting	input	but	endogenously	change	state	due	to	the	non-linear,	non-sequential	organization	implemented	in	them.	None	of	these	discussions,	however,	have	emphasized	that	biological	mechanisms	are	highly	controlled	systems.	Some	accounts	of	mechanisms	have	described	control	mechanisms,	such	as	neural	mechanisms	(Craver	2007)	or	circadian	clocks	(Bechtel	and	Abrahamsen	2009),	but	these	accounts	have	simply	looked	at	control	mechanisms	in	their	own	right	and	have	not	emphasized	how	they	exercise	control	over	other	mechanisms.		To	characterize	control,	it	is	helpful	to	begin	with	a	modified	perspective	on	mechanisms.	Mechanisms	perform	work,	and	this	requires	both	a	source	of	free	energy	and	ways	to	direct	it	so	as	to	carry	out	work.	Adopting	the	language	of	classical	mechanics,	several	theorists	have	characterized	what	directs	the	flow	of	free	energy	as	constraints	(Pattee	and	Rączaszek-Leonardi	2012;	Hooker	2013).	The	concept	of	constraints	was	introduced	into	classical	mechanics	to	account	for	the	behavior	of	macroscale	objects.	Constraints,	generally	in	the	form	of	chemical	bonds	between	particles,	reduce	the	degrees	of	freedom	in	which	individual	particles	can	move,	either	by	eliminating	motion	along	one	or	more	degrees	of	freedom	or	by	coupling	values	that	can	be	taken	on	two	or	more	degrees	of	
freedom.	In	contexts	in	which	there	is	a	source	of	free	energy,	such	constraints	can	serve	to	channel	the	flow	of	free	energy.	For	example,	a	pipe	can	restrict	water,	which	would	otherwise	spread,	to	flow	in	one	direction.	If	a	pipe	is	directed	downwards	towards	the	Earth’s	surface	then	the	free	energy	available	in	water	entering	the	top	of	the	pipe	can	perform	the	work	of	carving	out	a	gulley	at	the	bottom.			As	Hooker	(2013)	emphasizes,	although	the	term	constraint	connotes	restriction	or	limitation,	constraints	also	create	possibilities.	In	the	previous	example,	a	further	series	of	pipes	can	constrain	the	flow	of	water	so	as	to	rotate	a	mill	wheel	and	perform	the	work	of	grinding	grain.	Likewise,	the	constraints	that	fix	the	structure	of	a	protein	enable	it	to	catalyze	specific	reactions	by	bringing	reactants	into	close	proximity	so	that	available	free	energy	creates	or	breaks	chemical	bonds.	In	general,	components	of	biological	mechanisms	(as	well	as	human-built	machines)	serve	to	constrain	the	flow	of	available	free	energy	so	that	work	is	performed.	When	enzymes	bind	with	ATP,	for	example,	they	hydrolyze	it	and	direct	the	free	energy	that	is	released	to	carry	out	coupled	reactions.	Linking	to	the	more	traditional	vocabulary	introduced	by	the	mechanists	in	philosophy	of	science,	the	organization	of	components	into	mechanisms	constrains	free	energy	so	as	to	perform	the	work	required	to	generate	particular	phenomena.			Machines	and	biological	mechanisms	constrain	free	energy	to	perform	work,	but	unless	this	activity	can	be	controlled,	the	work	will	not	be	useful.	If	a	user	cannot	turn	off	a	machine,	it	will	continue	to	perform	its	activity,	even	if	that	is	no	longer	useful,	until	it	depletes	the	source	of	free	energy.	To	control	a	machine,	some	constraints	in	it	must	be	flexible,	capable	of	being	operated	on	by	something	external.	Most	machines	include	switches	that	allow	users	to	turn	them	off	by	stopping	the	flow	of	free	energy.	A	switch	is	a	constraint	that	can	be	altered	by	work	performed	on	it.	In	human-made	machines,	the	human	user	typically	performs	the	work	of	flipping	a	switch.	Some	constraints	may	take	a	continuum	of	values	as	work	is	performed	on	them,	leading	to	variable	activity	of	the	machines.	For	examples,	how	far	the	driver	of	a	car	depresses	the	accelerator	pedal	determines	the	opening	of	the	valve	that	constrains	the	flow	of	gasoline	into	the	engine	and	consequently	how	fast	the	car	moves.	In	some	human-built	machines	the	control	process	is	internalized.	The	governor	Watt	designed	for	the	steam	engine,	for	example,	relies	on	negative	feedback	to	alter	the	flexible	constraint	realized	in	valve	in	the	steam	pipe,	reducing	or	increasing	the	flow	of	steam	so	as	to	keep	a	flywheel	operating	at	the	same	speed.	Control,	then,	requires	a	second	mechanism	(e.g.,	the	driver	of	the	car	or	the	Watt	governor)	to	operate	on	a	flexible	constraint	in	the	primary	mechanism	that	is	directing	the	flow	of	free	energy.	The	control	mechanism	itself	requires	constraints	that	direct	free	energy	to	perform	its	work,	although	this	generally	requires	much	less	energy	than	the	primary	mechanism	employs	to	do	its	work.			As	important	as	control	mechanisms	are	in	human-built	machines,	they	are	even	more	important	in	the	case	of	biological	mechanisms.	Organisms	are	far-from-equilibrium	systems	that,	unless	they	perform	the	work	required	to	build	and	repair	their	own	parts,	will	dissipate	(Moreno	and	Mossio	2015).	Specialized	mechanisms	carry	out	the	construction	and	repair	processes.	If	they	are	to	keep	the	organism	functioning,	these	mechanisms	must	be	controlled	so	as	to	perform	their	activities	when	they	are	needed.	
Doing	so	at	other	times	can	be	just	as	bad	as	not	performing	them	when	they	are	required.	An	effective	control	mechanism,	accordingly,	does	not	just	operate	on	a	flexible	constraint	in	another	mechanism	but	must	do	so	in	response	to	a	condition	that	requires	the	primary	mechanism	to	operate	in	a	particular	manner.	A	control	mechanism	thus	contains	a	detector	that	constrains	its	operation.		An	important	challenge	in	understanding	the	functioning	of	biological	mechanisms	is	to	figure	out	how	they	are	controlled	by	other	mechanisms	that	perform	work	on	the	flexible	constraints	within	them.	However,	identifying	control	mechanisms	is	often	difficult.2	There	are	well	worked	out	heuristics	for	decomposing	and	explaining	the	functioning	of	primary	mechanisms	(Craver	and	Darden	2013)	and	mechanistic	philosophers	have	discussed	these	in	their	accounts	of	discovering	the	mechanisms	of	protein	synthesis	(Darden	and	Craver	2002)	and	metabolism	(Bechtel	2006).	These	accounts,	however,	have	been	silent	about	control	processes,	in	part	because	they	are	typically	not	active	in	the	experimental	setups	used	to	study	primary	mechanisms.	These	procedures	keep	conditions	constant	and	prevent	control	from	altering	the	mechanism’s	operation.	Diseases,	however,	are	contexts	in	which	these	control	mechanisms	are	often	manifest	as	a	diseased	cell	is	typically	one	in	which	a	control	system	has	been	altered.	Recent	research	on	cancer	is	unusually	informative	in	this	regard,	so	I	turn	to	it	in	the	next	section.		
3.	Cancer	and	Its	Hallmarks		The	role	of	control	operating	on	constraints	leading	to	abnormal	operation	of	cell	mechanisms	can	be	seen	by	examining	what	Hanahan	and	Weinberg	(2000,	2011)	characterize	as		“six	hallmarks	of	cancer—distinctive	and	complementary	capabilities	that	enable	tumor	growth	and	metastatic	dissemination”:		
• sustaining	proliferative	signaling	
• evading	growth	suppressors	
• resisting	cell	death	
• enabling	replicative	immortality	
• inducing	angiogenesis	
• activating	invasion	and	metastasis	Each	hallmark	involves	a	phenomenon	exhibited	in	normal	cells	but	which	occurs	with	increased	or	decreased	frequency	in	cancer	cells	due	to	altered	control	operating	on	the	responsible	mechanism.			
                                                      
2 An	exception	is	the	nervous	system,	which	is	paradigmatically	involved	in	controlling	other	activities	in	the	animal.	Yet,	even	in	examining	neural	mechanisms,	philosophers	have	focused	primarily	on	their	role	in,	for	example,	creating	mental	representations	of	space	(Craver	2007)	or	visual	inputs	(Bechtel	2008)	and	not	on	their	role	in	controlling	primary	mechanisms	involved	in,	for	example,	metabolism	or	muscle	contraction	(see,	however,	Keijzer,	van	Duijn,	and	Lyon	2013,	,	who	hypothesize	that	the	earliest	function	of	neurons	was	to	integrate	the	activity	of	muscles).	
The	first	hallmark	is	perhaps	the	most	widely	recognized	characteristic	of	cancer—cancer	cells	proliferate,	replicating	in	an	uncontrolled	fashion.	Normal	somatic	cells	divide	as	well,	but	after	the	developmental	stage,	they	reach	a	homeostatic	state.	Control	mechanisms	shut	down	division	unless	the	cell	receives	a	signal,	such	as	TGF-α,	indicating	a	need	for	the	cell	to	replicate.	In	cancer	cells	this	control	is	removed	and	cells	continue	to	proliferate	independently	of	such	signals.	The	second	hallmark	is	closely	related.	Cells	in	normal	tissue	do	not	just	fail	to	receive	signals	to	proliferate	but	actively	suppress	proliferation	in	response	to	other	signals,	such	as	TGF-β.	Antigrowth	signals	can	block	proliferation	through	a	control	mechanism	that	forces	cells	into	a	quiescent	state	in	which	the	cell	cycle	stops	except	when	the	cell	receives	a	signal	to	proliferate.	By	altering	control	mechanisms,	cancer	cells	not	only	initiative	division	on	their	own,	but	also	escape	the	effects	of	mechanisms	that	would	normally	suppress	proliferation.		The	third	hallmark	is	that	cancer	cells	shut	down	normal	cell	processes	that	enable	recycling	of	damaged	or	unneeded	biological	structures.	When	a	cell	is	too	disrupted	to	continue	normal	function,	control	mechanisms	typically	activate	primary	mechanisms	that	perform	apoptosis	or	programmed	cell	death.	Over	the	course	of	30	to	120	minutes,	a	bevy	of	these	mechanisms	within	the	cell	are	turned	on	to	dismantle	the	cell	by	disrupting	its	membrane,	breaking	down	the	cytoplasmic	and	nuclear	skeletons,	extruding	the	cytosol,	degrading	the	chromosomes,	and	fragmenting	the	nucleus.	Nearby	cells	then	engulf	the	remains.	While	apoptosis	and	necrosis	eliminate	cells,	the	process	of	autophagy	recycles	components	within	cells	either	when	they	are	no	longer	needed	or	when	they	are	damaged	(Feng	et	al.	2014).	In	the	course	of	autophagy,	intracellular	vesicles,	autophagosomes,	envelop	organelles	such	as	mitochondria	and	ribosomes	and	then	merge	with	lysosomes	that	degrade	the	enclosed	organelle	into	its	molecular	components,	which	are	then	reused	in	biosynthetic	processes.	By	interfering	with	the	control	mechanisms	that	activate	these	processes,	cancer	cells	avoid	these	fates	that	normally	befall	disrupted	cells	and	cell	components	and	continue	to	maintain	themselves	and	proliferate.		The	fourth	and	fifth	hallmarks	involve	altering	control	mechanisms	to	reactivate	cellular	processes	that	are	normally	down-regulated	in	mature	somatic	cells.	In	multicellular	organisms,	Hayflick	and	Moorhead	(1961)	discovered	that	human	embryonic	cells	only	divide	a	limited	number	of	times	and	then	enter	into	a	senescent	state.	The	number	of	possible	divisions	is	known	as	the	Hayflick	limit,	which	was	subsequently	found	to	correlate	with	an	already	known	process	of	telomere	shortening.	In	each	cell	replication	telomere	repeats	are	removed.	When	the	last	telomeres	are	removed,	the	ends	of	chromosomal	DNA	fuse.	Stem	cells	provide	an	exception	to	the	progressive	removal	of	telomeres.	In	stem	cells,	the	enzyme	telomerase	adds	rather	than	removes	telomeres.	Telomerase	is	down-regulated	in	most	somatic	tissue,	but	in	cancer,	as	in	stem	cells,	telomerase	is	activated,	allowing	cells	to	acquire	replicative	immortality.				The	fifth	hallmark	involves	inhibiting	the	control	mechanism	that	in	mature	cells	turns	off	the	embryonic	processes	of	generating	new	vasculature,	needed	to	provide	oxygen	and	nutrients	and	remove	waste	products.	One	of	these	processes,	angiogenesis,	involves	sprouting	new	vessels	from	ones	already	generated.	Once	development	is	complete,	control	mechanisms	generally	block	angiogenesis,	allowing	it	to	occur	only	transiently	in	contexts	
such	as	wound	healing	and	female	reproductive	cycling.	When	this	suppression	is	inhibited	in	cancer,	the	mechanism	of	angiogenesis	continually	generates	new	vessels	to	support	the	ongoing	proliferation	of	cells.			The	last	hallmark	of	cancer,	invasion	of	other	tissue	and	metastasis,	reverses	the	control	mechanisms	that	keep	somatic	cells	in	a	quiescent	state	adhering	to	epithelial	cell	sheets.	This	enables	the	cancer	cell	to	reactivate	mechanisms	that	are	normally	active	only	in	development.	Since	these	control	mechanisms	were	mostly	were	discovered	by	developmental	biologists,	not	cancer	researchers,	I	will	not	focus	on	this	hallmark.			
4.	Cancer	Hallmarks	Reveal	Control	Mechanisms	in	Normal	Cells		So	far	I	have	appealed	to	the	hallmarks	of	cancer	to	identify	the	existence	of	control	mechanisms	that	are	altered	in	cancer	without	going	into	any	details	about	how	they	operate.	But	cancer	research	has	also	revealed	many	of	the	parts	and	operations	constituting	these	control	mechanisms.	In	this	section	I	discuss	how,	starting	from	identification	of	genes	that	are	often	mutated	in	cancer,	researchers	identified	the	parts	and	operations	of	numerous	of	these	control	mechanisms.	(The	control	mechanisms	consist	of	proteins	coded	for	by	the	genes,	but	researchers	often	find	it	convenient	to	skip	over	the	steps	of	transcription	and	translation	and	simply	slide	between	referring	to	genes	and	referring	proteins.	I	follow	that	practice.)	As	a	reference	point	for	subsequent	discussions,	I	reproduce	a	wiring	diagram	of	the	most	prominent	control	circuits	(from	Hanahan	and	Weinberg	2000)	that	presents	the	largely	sequential	pathways	of	reactions	that	constitute	the	control	mechanisms	that	regulate	particular	primary	cell	mechanisms	in	normal	cells	that	are	altered	in	the	hallmarks	of	cancer.			Discovery	of	these	mechanisms	began	with	the	discovery	of	a	few	genes	that	were	frequently	mutated	in	cancer	cells.	Research	in	the	1960s	through	the	1980s	resulted	in	the	identification	of	Hras	and	Kras	as	the	first	oncogenes—genes	that	when	mutated	initiate	the	progression	into	cancer	(Ellis	et	al.	1981).		Other	research	during	the	same	time	identified	different	genes,	starting	with	Rb,	whose	products	normally	serve	to	suppress	development	of	cancer	but	when	mutated	allow	cancer	to	develop	(Murphree	and	Benedict	1984).	These	came	to	be	known	as	tumor	suppressor	genes.	In	the	attempt	to	understand	how	those	genes	functioned	in	control	mechanisms,	research	revealed	many	other	genes/proteins	with	which	they	interacted,	ultimately	identifying	pathways—sequences	of	reactions,	each	producing	a	product	that	is	an	input	to	the	next	reaction.	These	pathways	correspond	closely	to	philosophical	accounts	that	view	mechanisms	as	proceeding	from	“start	or	set-up	to	finish	or	termination	conditions”	(Machamer,	Darden,	and	Craver	2000,	3).	Research	on	other	biological	mechanisms,	such	as	those	involved	in	extracting	energy	from	metabolites,	also	revealed	pathways.	The	pathways	consisting	of	the	proteins	coded	for	by	genes	mutated	in	cancer,	however,	are	not	involved	directly	in	metabolizing	foodstuffs	or	synthesizing	biological	structures	but	in	controlling	these	primary	mechanisms.	
	Figure	1.	Hanahan	and	Weinberg’s	representation	of	pathways	regulating	normal	cells	that	are	mutated	in	cancer.	The	proteins	coded	by	the	best-known	oncogenes	(Ras,	Myc)	and	tumor	suppressor	genes	(p53	and	PTEN)	are	shown	in	red.	Reprinted	from	Cell,	Vol.	100,	Hanahan,	D.	and	Weinberg,	R.	A.,	The	Hallmarks	of	Cancer,	Figure	2,	©	2000,	with	permission	from	Elsevier.		I	begin	with	control	mechanisms	that	normally	prevent	cell	division	except	when	the	cell	receives	signals	from	their	environment	that	indicate	a	need	for	division.	Mutations	to	the	two	oncogenes	Hras	and	Kras	led	to	proliferation.	To	determine	how,	researchers	first	identified	a	number	of	other	proteins	with	which	they	interact:	Raf,	MEK,	MAPK,	etc.	These	interact	sequentially	in	the	pathway	shown	on	the	left	in	Figure	1.	For	signaling	along	this	pathway	to	result	in	proliferation,	the	signal	must	be	maintained.	This	challenged	researchers	to	determine	how	the	Ras	proteins	generate	a	sustained	signal.	They	discovered	that	Ras	proteins	actively	transduce	signals	when	they	form	complexes	with	GTP.	Normal	Ras	proteins	function	as	GTPases	and	hydrolyze	bound	GTP	into	GDP.	When	GDP	replaced	GTP,	Ras	no	longer	transduces	signals.	This	revealed	that	Ras	normally	exercises	control	by	functioning	as	a	switch	that	turns	itself	off	by	hydrolyzing	GTP	to	GDP,	thus	insuring	that	the	proliferation	signal	is	active	for	only	a	short	period	(Vetter	and	Wittinghofer	2001).	The	mutations	that	turn	Ras	proteins	into	oncogenes	impair	their	ability	to	function	as	GTPases,	thus	blocking	the	switching	operation	that	would	normally	abort	signaling.	A	switch	operates	on	a	flexible	constraint	through	which	the	work	of	a	mechanism	can	be	changed.	This	is	the	first	of	several	switches	revealed	by	cancer	research	which,	when	disrupted,	result	in	the	hallmarks	of	cancer.			
Another	example	of	a	switch	is	found	in	the	control	mechanism	shown	in	the	lower	left	in	Figure	1.	When	survival	factors	such	as	IGF1	bind	to	RTKs,	they	activate	Phosphoinositide	3-kinase	(PI3-kinase),	which	in	turn	initiates	separate	proteolytic	cascades	leading	to	replication	and	angiogenesis.	Normally	PTEN	(phosphatase	and	tensin	homologue)	degrades	the	immediate	product	of	PI3-kinase,	phosphatidylinositol	(3,4,5)	trisphosphate	(PIP3)	to	PIP2,	switching	off	the	signaling.	When	PTEN	is	mutated,	however,	this	switching	does	not	occur,	leading	to	continual	replication	and	angiogenesis.			Research	on	tumor	suppressor	genes—genes	whose	products	normally	prevent	development	of	tumors	but	when	mutated	allow	tumors	to	develop—revealed	other	control	mechanisms	disrupted	in	cancer.	Two	of	the	best-studied	tumor	suppressor	proteins	are	Rb	retinoblastoma-associated)	and	TP53.	Rb	(shown	center	top	of	the	nucleus	in	Figure	1)	integrates	signals	mostly	from	extracellular	sources	(especially	growth	inhibitory	signals)	and	gates	whether	the	cell	can	proceed	through	the	cell	cycle	(Burkhart	and	Sage	2008).	TP53	(right	side	of	the	nucleus	in	Figure	1),	on	the	other	hand,	responds	to	stress	and	indicators	of	abnormal	operation	of	cell	mechanisms	and,	depending	on	severity,	blocks	further	progression	of	the	cell	cycle	(senescence)	or	initiates	apoptosis.			To	illustrate	this	process	in	more	detail,	I	focus	on	control	over	apoptosis,	for	which	research	has	revealed	a	complex	control	system.	The	components	of	the	apoptosis	mechanism	(the	proteases	caspase	3-7)	are	already	in	place	in	mitochondria	in	normal	cells	but	limited	by	a	flexible	constraint	from	initiating	their	apoptotic	activities	until	they	bind	with	either	Caspase	8	or	Caspase	9.	The	availability	of	Caspase	9	is	further	controlled	by	another	flexible	constraint,	an	“apoptotic	trigger”	involving	counterbalanced	pro-	and	anti-apoptotic	members	of	the	Bcl-2	family	of	regulatory	proteins.	Members	of	the	Bcl-2	family	inhibit	Caspase	9	by	binding	to	and	suppressing	the	activity	of	Bax	and	Bak.	Bax	and	Bak	are	embedded	in	the	outer	mitochondrial	membrane	and	when	not	suppressed,	disrupt	the	integrity	of	the	outer	mitochondrial	membrane.	This	causes	the	release	of	cytochrome	c	and	Apaf-1	that	together	activate	Caspase	9.	More	recent	research	has	revealed	even	more	complexity	in	the	mechanism.	Both	Bcl-2,	which	suppresses	the	trigger,	and	Bax	and	Bak,	which	activate	the	trigger,	possess	protein-protein	interaction	domains	known	as	BH3	motifs	(Lowe,	Cepero,	and	Evan	2004).	The	proteins	that	determine	the	setting	of	the	switch	and	thus	whether	apoptosis	occurs	each	contain	a	single	BH3	that	enables	them	to	bind	either	with	Bcl-2	or	with	Bax	and	Bak	(Adams	and	Cory	2007;	Willis	and	Adams	2005).	Control	is	thus	achieved	by	proteins	operating	on	flexible	constraints	in	the	control	mechanisms	that	subsequently	affect	flexible	constraints	in	the	mechanisms	carrying	out	apoptosis.			Whereas	apoptosis	dismantles	whole	cells	to	provide	resources	to	other	cells,	autophagy	dismantles	and	recycles	organelles	such	as	mitochondria	and	ribosomes	within	cells.	Like	apoptosis,	it	is	a	process	that	can	contribute	to	fighting	cancer.	The	autophagy	mechanism	normally	operates	at	a	low	level,	only	dismantling	poorly	functioning	organelles	by	enveloping	them	and	then	fusing	with	a	lysosome	to	dismantle	them.	Control	mechanism	operate	on	the	autophagy	mechanism	to	increase	it	activity	under	stress	conditions	such	as	nutrient	deprivation	(Mizushima	2007).	Beclin-1,	a	member	of	the	BH3-only	family	discussed	above	as	controlling	apoptosis,	is	also	a	key	element	in	controlling	autophagy.	It	
is	normally	bound	to	Bcl-2,	but	when	its	stress	sensors	are	activated,	it	uncouples	from	Bcl-2	to	initiate	autophagy.	Thus	stress	conditions	in	the	cell	resulting	from	early	progression	to	cancer	can	trigger	autophagy	as	a	defense	mechanism.	Accordingly,	one	of	the	common	steps	in	the	development	of	cancer	involves	disabling	the	control	mechanisms	that	initiate	autophagy	(White	et	al.	2010).	But	ironically,	autophagy	can	also	be	invoked	to	protect	cancer	cells	when	they	are	placed	in	stress	conditions	as	a	result	of	nutrient	deprivation,	radiotherapy,	or	cytotoxic	drugs.	This	can	result	in	cancer	cells	shrinking	into	a	state	of	reversible	dormancy,	enabling	tumors	to	grow	again	after	treatment	with	anticancer	drugs	has	ceased	(White	and	DiPaola	2009).			In	this	section	I	have	identified	several	control	mechanisms	of	normal	cells	that,	when	altered,	result	in	particular	hallmarks	of	cancer.	Except	for	the	last,	each	of	these	involves	control	pathways	shown	in	Figure	1.	Two	central	points	emerge	from	this	discussion.	In	each	case	the	mechanisms	being	regulated	reside	in	normal	cells	and	are	active	in	appropriate	conditions	in	these	cells.	Turning	these	mechanisms	on	in	cancer	requires	modifying	the	control	mechanisms	that	normally	turn	them	off.	Second,	in	each	case	there	are	multiple	control	factors,	typically	operating	sequentially	in	pathways	that	result	in	altering	the	functioning	of	the	primary	cell	mechanisms.			
5.	Cancer	and	Metabolic	Regulation		Several	of	the	control	mechanisms	I	have	discussed	so	far	operate	several	steps	removed	from	the	primary	mechanisms	they	control.	Glucose	metabolism	provides	a	useful	example	in	which	research	has	revealed	how	control	mechanisms	act	on	primary	mechanisms.	The	primary	mechanism	for	metabolizing	glucose	was	largely	characterized	by	the	1930s	through	the	work	of	Embden,	Meyerhof,	and	others	(Needham	1971;	Fruton	1972;	Bechtel	2006).	(The	key	operations	are	shown	in	the	vertical	pathway	of	reactions	in	Figure	3	below.)	Clues	to	its	altered	functioning	in	cancer	were	already	available	when	Warburg	(1930,	1956)	reported	that	cancer	cells	exhibit	a	marked	increase	in	glucose	consumption	compared	with	normal	cells.	Moreover,	Warburg	noted	that	cancer	cells	often	secrete	large	quantities	of	lactate,	a	product	of	glucose	metabolism	that	is	usually	depleted	through	the	subsequent	mechanism	of	oxidative	metabolism.3	Since	glycolysis	only	generates	2	molecules	of	ATP	per	molecule	of	glucose	compared	with	the	36	molecules	of	ATP	generated	in	oxidative	metabolism,	the	energy	harvested	is	massively	reduced	in	cancer	cells.	Warburg	assumed	that	mitochondria,	in	which	oxidative	metabolism	is	carried	out	through	the	tricarboxylic	acid	cycle	(TCA),	are	damaged	in	cancer	cells	and	that	this	forced	cancer	cells	to	rely	totally	on	glycolysis.	However,	subsequent	studies	found	that	the	mitochondria	in	most	cancer	cells	are	fully	functional.	This	revealed	that	the	reliance	on	glycolysis	without	continuing	to	oxidative	metabolism	was	due	to	altered	control	in	the	case	of	cancer.4		
                                                      
3 Lactate is then released into the intercellular matrix where, through the Cori Cycle, it is 
transported back to the liver and resynthesized to glucose, at considerable expense of ATP that is 
procured from normal oxidative metabolism in healthy cells.  
4 In addition to glucose metabolism, glutamine metabolism is altered, providing access to needed 
amino acids (Pavlova and Thompson 2016). 
	Cancer	researchers	have	identified	two	points	at	which	the	glycolytic	mechanism	is	altered	in	cancer.	At	the	beginning	of	the	pathway	the	uptake	of	glucose	by	the	cell	is	increased	and	at	the	end	of	the	process	the	products	of	glucose	metabolism	are	redirected	away	from	the	TCA	cycle.	These	are	two	points	at	which	there	are	flexible	constraints	that	are	the	target	of	control	processes.	I	focus	now	on	control	at	the	beginning	of	the	pathway	and	return	to	control	at	the	end	of	the	pathway	below.		Glucose	transporter	1	(GLUT1)	is	the	enzyme	that	transports	glucose	across	the	cellular	membrane.	The	rate	at	which	it	does	so	is	controlled	by	hypoxia	inducible	factor-1	(HIF-1),	which	alters	the	rates	both	of	the	transcription	of	GLUT1	and	the	translocation	of	the	GLUT1	protein	from	the	endomembrane	to	the	cell	surface.	This,	however,	is	not	the	only	point	at	which	HIF-1	alters	constraints	in	glycolysis.	As	shown	in	Figure	2,	it	also	binds	to	and	so	alters	the	operation	of	many	of	the	enzymes	in	the	glycolytic	pathway	itself	(Semenza	2010).	(I	return	to	other	functions	of	HIF-1	shown	in	Figure	2	below.)	In	normal	cells	oxygen,	when	it	is	available,	renders	HIF-1	unstable	so	that	it	is	broken	down	by	the	ubiquitin–proteasome	pathway.	As	a	result,	glucose	uptake	is	normally	reduced	when	oxygen	is	available.	The	lack	of	oxygen	in	hypoxia	leaves	HIF-1	in	place,	resulting	in	an	increase	in	glycolysis.	Thus,	HIF-1	operates	as	a	switch	controlled	by	oxygen,	yielding	increased	glycolysis	in	conditions	in	which	it	is	the	only	source	of	free	energy.	In	cancer	this	control	process	is	disrupted	so	that	HIF-1	is	no	longer	degraded	by	oxygen	and	continues	to	maintain	high	rates	of	glycolysis.		
	Figure	2.	The	role	of	HIF-1	in	regulating	cell	process.	Reprinted	by	permission	from	Springer	Nature:		Molecular	Biology	Reports,	Cancer	Metabolism	and	the	Warburg	Effect:	The	Role	of	Hif-1	and	Pi3k,	Courtnay,	R.,	Ngo,	D.	C.,	Malik,	N.,	Ververis,	K.,	Tortorella,	S.	M.,	and	Karagiannis,	T.C.	©	2015,	Figure	2.			The	reliance	on	the	far	less	efficient	process	of	glycolysis	rather	than	oxidative	metabolism	in	cells	needing	energy	to	proliferate	at	first	seems	counterintuitive.	Potter	(1958)	proposed	an	explanation:	the	intermediates	of	glycolysis	also	figure	in	metabolic	reactions	
that	produce	other	molecules	used	to	synthesize	various	biological	compounds	(e.g.,	fatty	acids,	cholesterol,	nucleotides)	needed	in	proliferating	cells.	Vander	Heiden,	Cantley,	and	Thompson	(2009)	have	revived	and	further	developed	Potter’s	proposal.	The	arrows	projecting	horizontally	from	the	intermediates	glucose-6-phosphate,	fructose-6-phosphate,	dihydroxyacetone-phosphate	(DHA-P),	and	3-P-glycerate	in	Figure	3	indicate	reactions	that	synthesize	other	biological	compounds.	For	example,	the	first	reaction	product	in	the	pathway,	glucose-6-phosphate,	feeds	into	the	pentose	phosphate	pathway	(PPP),	in	which			
	Figure	3.	The	glycolytic	pathway	and	the	TCA	cycle.	GLUT1	transports	glucose	into	the	cytoplasm	where	it	can	enter	the	glycolytic	pathway.	Red	horizontal	arrows	identify	alternative	pathways	from	key	intermediates	in	glycolysis	that	are	activated	in	aerobic	glycolysis.	Other	key	regulators	such	as	PKM2	are	shown	in	blue.	Reprinted	from	Cell	Metabolism,	Vol.	23,	Pavlova,	N.	N.	and	Thompson,	C.	B.	The	Emerging	Hallmarks	of	Cancer	Metabolism,	Figure	4,	©	2016,	with	permission	from	Elsevier.	
glucose-6-phophate	becomes	partially	oxidized	to	yield	ribose-5-phosphate,	which	in	turn	is	a	constituent	of	nucleotides.	The	alteration	of	the	control	mechanisms	that	initiate	glycolysis	also	increase	the	generation	of	these	other	products	(Pavlova	and	Thompson	2016).	Cancer,	once	again,	alters	control	mechanisms	to	increase	reliance	on	primary	mechanisms	that	normal	cells	also	use,	albeit	more	sparingly.		I	have	focused	on	only	one	of	several	points	of	control	in	the	glycolytic	mechanism	that	are	altered	in	cancer.	Individual	enzymes	in	the	glycolytic	pathway	are	also	regulated,	including	phosphofructokinase,	which	catalyzes	the	key	irreversible	step	from	fructose-6-phosphate	to	fructose-1,6-pyrophosphate.	Rather	than	developing	these,	I	turn	briefly	to	regulation	at	the	end	of	the	pathway.	Even	with	control	mechanisms	that	increase	the	shunting	of	glycolytic	intermediates	into	alternative	pathways,	a	good	deal	of	phosphoenolpruvate	is	dephosphorylated	into	pyruvate.	If	pyruvate	dehydrogenase	were	then	to	convert	pyruvate	to	acetyl-CoA,	it	would	proceed	through	the	TCA	cycle,	generating	ATP.	This	would	inhibit	the	action	of	phosphofructokinase,	an	allosteric	enzyme	that	is	inhibited	by	ATP	while	it	also	consumed	ATP	to	phosphorylate	Fructose-6-phosphate.	A	further	function	of	HIF-1,	as	shown	in	Figure	2,	is	to	up	regulate	pyruvate	dehydrogenase	kinase	1	(PDK1).	As	shown	in	Figure	3,	PDK1	inhibits	pyruvate	dehydrogenase	and	stops	entry	into	the	TCA	cycle.	HIF-1	also	up-regulates	lactate	dehydrogenase	(LDH),	which	converts	pyruvate	to	lactate.	This	accounts	of	the	accumulation	of	lactate	and	its	transport	out	of	the	cell	in	cancer.			Research	on	the	control	processes	through	which	glucose	metabolism	is	altered	in	the	course	of	cancer	has	thus	revealed	a	host	of	flexible	constraints	in	the	glycolytic	mechanism	on	which	control	can	be	exercised	by	other	molecules	such	as	HIF-1.	In	normal	cells	this	control	serves	to	reduce	the	rate	of	glycolysis	and	to	direct	the	product,	pyruvate,	into	the	TCA	cycle.	These	control	mechanisms	are	altered	by	the	failure	to	degrade	HIF-1	in	the	presence	of	oxygen.	As	a	result,	the	rate	of	glycolysis	is	increased	in	cancer	and	many	of	its	intermediates	are	used	to	synthesize	other	compounds	required	in	cancer	cells.	By	revealing	these	flexible	constraints	and	the	control	that	can	be	exercised	on	them,	cancer	research	provides	a	different	perspective	on	the	glycolytic	mechanism.	Rather	than	operating	from	start	to	termination	conditions	whenever	glucose	is	available	(and	not	suppressed	by	already	accumulated	ATP5),	the	glycolytic	mechanism	is	seen	to	contain	a	host	of	flexible	constraints	that	are	operated	on	by	various	control	processes.		
6.	An	Integrated	Network	of	Controllers		The	research	discussed	so	far	shows	that	investigating	cancer	has	revealed	a	plethora	of	control	pathways	that	when	disrupted	lead	to	hallmarks	of	cancer.	As	is	common	in	mechanistic	research,	the	investigation	started	by	identifying	individual	genes	that	are	frequently	mutated	in	cancer	(Bechtel	and	Richardson	1993/2010)	and	then	reasoned	
                                                      
5 The control of phosphofructokinase by ATP had been discovered independently as a result of 
discovery of oscillations in the concentrations of NAD+ and other intermediates and 
determination that these oscillations resulted from the feedback of ATP on the mechanism 
(Ghosh and Chance 1964). 
forwards	and	backwards	(Craver	and	Darden	2013)	to	identify	operations	in	the	control	mechanisms.	Researchers	attempted	to	organize	these	operations	into	pathways	characterized	by	sequences	of	reactions	and	then	to	link	these	pathways	to	flexible	constraints	in	primary	mechanisms.	But	this	research	also	reveals	that	these	pathways	interconnect.	Although	Figures	1-3	show	pathways,	they	also	reveal	numerous	points	of	connection.	If	one	follows	these	out,	it	becomes	apparent	that	in	fact	the	control	systems	are	not	independent	but	integrated	into	a	single	network.	In	this	section	I	will	note	a	couple	of	these	points	of	integration	and	then	demonstrate	how	network	analyses	are	now	playing	crucial	roles	in	advancing	the	understanding	of	both	cancer	and	control	in	normal	cells.			Above	I	focused	on	the	roles	mutated	Ras	proteins	play	in	promoting	proliferation,	but	they	also	regulate	many	other	mechanisms	responsible	for	hallmarks	of	cancer.	When	the	signal	they	produce	is	too	strong,	apoptosis	is	induced	by	activating	Rb	and	TP53.	In	addition,	Ras	proteins,	as	well	as	other	oncogenes,	up	regulate	GLUT1	(Murakami	et	al.	1992),	thereby	increasing	glycolysis.	Ras	proteins	also	figure	in	the	key	alternative	pathways	in	glycolysis—in	the	pentose	phosphate	pathway,	they	up	regulate	two	key	enzymes,	transketolase-like	1	(TKTL1)	and	transaldolase	(TALDO).	These	enzymes	are	in	turn	suppressed	by	TP53,	so	when	Ras	proteins	are	sufficiently	active	so	as	to	activate	TP53,	it	down-regulates	these	enzymes.	Thus,	Ras	proteins	are	implicated	in	proliferation,	apoptosis,	and	altered	metabolism.			HIF-1	also	figures	in	control	of	many	cell	mechanisms.	Above	I	only	addressed	the	pathways	on	the	left	side	of	Figure	2	through	which	HIF-1	operates	to	control	glycolysis.	But	the	figure	also	indicates	that	HIF-1	plays	a	role	in	regulating	vascular	endothelial	growth	factor	(VEGF),	which	encodes	ligands	that	control	new	blood	vessel	growth	during	embryonic	and	postnatal	development	and	is	up-regulated	in	hypoxia	and	cancer	(Ferrara	2009).	Thus,	it	also	helps	explain	the	hallmark	of	angiogenesis.	Angiogenesis	is	also	controlled	by	lactate	resulting	from	the	altered	control	HIF-1	exerts	over	glycolysis	in	cancer	cells	(Végran	et	al.	2011).	Finally,	HIF-1	up-regulates	erythropoietin	(EPO),	which	stimulates	production	of	red	blood	cells.	By	controlling	these	two	processes,	HIF-1	functions	to	increase	oxygen	and	nutrient	delivery	beyond	what	is	required	in	normal	cell	function.	This	research	has	revealed	that	HIF-1	performs	control	operations	with	respect	to	a	diverse	range	of	cell	mechanisms.			Yet	another	example	in	which	research	has	pointed	to	the	interaction	of	control	processes	is	provided	by	the	protein	subunit	of	telomeres,	telomere	reverse	transcriptase	(TERT).	In	addition	to	its	role	in	adding	telomeres	and	thus	defeating	the	Hayflick	limit	on	cell	replication,	noted	above,	TERT	also	functions	as	a	cofactor	of	β-catenin/LEF	transcription	factor	complex	that	figures	in	the	Wnt	pathway	(not	discussed	above	but	shown	in	the	upper	left	of	Figure	1).	The	Wnt	pathway	is	important	in	regulating	the	cell	cycle	as	it	activates	replication	in	stem	cells	(Park	et	al.	2009;	Bryja,	Červenka,	and	Čajánek	2017).	TERT	has	also	been	shown	to	have	effects	on	regulating	apoptosis	(Kang	et	al.	2004)	and	DNA-damage	repair	(Masutomi	et	al.	2005).		These	various	findings	illustrate	something	that	is	already	apparent	in	Figure	1:	the	different	pathways	involved	in	control	of	cell	processes	are	not	independent,	but	interact	at	
numerous	points.	Although	the	notion	of	pathway	plays	an	important	role	when	tracing	out	the	individual	steps	in	specific	control	mechanisms,	it	does	not	provide	the	best	way	to	understand	these	interactions.	Conceptualizing	control	in	terms	of	networks	provides	an	alternative	framework	that	is	increasingly	being	employed	in	cancer	research	to	understand	control	systems	that	are	operative	in	both	cancer	and	normal	cells.	Network	diagrams	consist	of	nodes	and	edges,	in	which	nodes	stand	for	various	kinds	of	entities	(genes,	proteins,	etc.)	and	edges	for	various	types	of	interactions	between	nodes.	Pathway	analyses	can	be	transformed	into	network	diagrams	by	abstracting	from	specific	details	(Figure	1	effectively	does	that),	but	there	are	other	strategies	for	constructing	network	models	that	can	yield	additional	insights	into	control	systems.			Researchers	working	on	model	organisms	such	as	yeast	have	created	network	diagrams	based	on	a	variety	of	types	of	gene	and	protein	interaction	data.	For	example,	the	yeast	two-hybrid	technique	reveals	which	proteins	in	a	cell	are	able	to	form	complexes	whereas	investigations	of	synthetic	lethality	indicate	genes	that	interact	in	the	generation	of	traits.	In	Bechtel	(2017,	in	press)	I	have	shown	how	analyses	of	these	networks	have	provided	new	insights	into	the	mechanisms	involved	in	yeast	cells.6	Similar	data	is	now	being	generated	for	human	cells,	but	in	the	meantime	investigators	have	also	found	it	productive	to	predict	gene	and	protein	interactions	on	the	basis	of	homology	between	model	organisms	and	humans.	These	networks	alone	do	not	provide	information	about	where	proteins	are	expressed	in	cells	or	the	biological	processes	to	which	they	contribute,	crucial	for	a	mechanistic	understanding.	However,	network	researchers	have	developed	strategies	for	annotating	these	networks	with	this	type	of	information	using	resources	such	as	Gene	Ontology	(GO)	(Ashburner	et	al.	2000).7			Given	the	number	of	interactions	between	genes	and	proteins	that	these	techniques	reveal,	the	resulting	network	diagrams	initially	appear	as	hairballs	in	which	no	interpretable	patterns	can	be	identified.	Network	researchers	have	developed	a	number	of	analytical	tools,	available	in	network	representation	platforms	such	as	Cytoscape	(Shannon	et	al.	2003),	to	make	sense	of	networks.	A	particularly	useful	type	of	analysis	that	Cytoscape	facilitates	is	identifying	clusters	in	networks—sets	of	nodes	that	are	especially	densely	interconnected.	Network	researchers	often	interpret	dense	clusters	of	highly	interconnected	nodes	in	protein-protein	interaction	networks	as	mechanisms	engaged	in	particular	tasks	whereas	connections	between	these	modules	are	interpreted	as	vehicles	of	control.	Other	tools	in	Cytoscape	that	help	turn	hairballs	into	interpretable	networks	are	layout	algorithms	(such	as	force-based	ones	that	treat	edges	like	springs,	pulling	connected	nodes	situated	far	from	each	other	together	and	pushing	those	very	close	to	each	other	slightly	apart)	and	filtering	tools	to	look	selectively	at	particular	nodes	and	edges.			
                                                      
6 There is disagreement as to whether network analyses complement (Matthiessen 2017) or 
compete with (Braillard 2010) mechanistic accounts. In Green et al. (2018), we discuss a range 
of examples of network analyses, ranging from those that integrate with mechanistic accounts to 
those that abstract from concrete mechanisms to focus on dynamics. 
7 For a philosophical examination of the classification scheme employed in GO, see Leonelli 
(2010). 
I	will	present	one	example	in	which	researchers	extended	a	pathway	analysis	into	a	network	analysis.	From	Reactome,	a	database	of	pathways,	and	a	variety	of	resources	providing	protein	and	gene	interaction	data,	Wu,	Feng,	and	Stein	(2010)	developed	a	large	network	of	10,956	proteins	and	209,988	interactions,	which	they	termed	the	Functional	Interaction	(FI)	network.	They	used	this	network	to	interpret	glioblastoma	data	compiled	in	The	Cancer	Genome	Atlas’s	characterization	of	206	glioblastomas	(Cancer	Genome	Atlas	Research	Network	2008).	The	researchers	identified	those	proteins	in	FI	that	corresponded	to	genes	identified	as	mutated	in	at	least	two	TCGA	samples.	They	then	included	the	fewest	additional	proteins	in	FI	to	create	a	connected	network	including	at	least	70%	of	these	altered	genes.	They	proposed	that	the	resulting	network,	shown	in	Figure	4,	is	the	core	subnetwork	of	mutations	in	glioblastoma.	Since	they	had	begun	with	a	pathway	analysis	from	Reactome,	they	were	able	to	identify	those	proteins	in	their	proposed	core	subnetwork	that	belonged	to	four	pathways—p53,	focal	adhesion,	signaling	by	PDGF,	and		
	Figure	4.	Core	subnetwork	Wu,	Feng,	and	Stein	extracted	from	TCGA	glioblastoma	data	with	identification	of	genes	in	four	pathways	shown	in	shaded	regions.	The	color	of	the	nodes	indicates	genes	shared	in	another	sample	of	glioblastoma	tumors	(yellow)	or	not	shared	(blue).	Red	indicates	those	nodes	added	to	connect	the	network.	Node	size	indicates	frequency	of	mutation	in	TCGA	sample.	This	appears	as	Figure	8A	in	Wu,	Feng,	and	Stein	(2010)	and	is	reprinted	from	BioMed	Central	under	the	Creative	Commons	Attribution	(CC-BY)	license.		
cell	cycle	pathways.	These	are	shown	in	shading	in	Figure	4.	The	figure	reveals	both	that	many	of	the	proteins	in	the	network	belong	to	these	four	pathways	and	also	that	these	pathways	are	highly	intertwined.		Network	analyses	go	beyond	the	pathway	analyses	in	revealing	the	interconnected	nature	of	the	control	mechanisms	operative	in	normal	cells	and	disrupted	in	cancer.	In	particular,	they	provide	a	strategy	to	avoid	thinking	of	control	in	purely	hierarchical	terms,	with	controllers	residing	at	a	higher	level	than	the	processes	they	control.	As	noted	above,	in	human-made	machines,	control	processes	are	organized	hierarchically	to	enable	human	operators	to	determine	the	activity	of	the	machine.	But	in	biological	organisms,	control	mechanisms	generally	terminate	within	the	organism.	Different	components	of	the	organism	initiate	control	processes	that	regulate	other	components,	but	this	does	not	lead	to	a	top-level	controller	overseeing	the	whole	operation.	Instead,	the	research	reveals	a	network	in	which	multiple	control	mechanisms	are	embedded	and	through	which	they	interact.	As	a	result	of	their	interactions,	when	a	gene	is	mutated,	as	in	cancer,	it	does	not	alter	the	behavior	of	just	one	primary	mechanism,	but	often	a	wide	range	(giving	rise	to	the	multiple	hallmarks	of	cancer	discussed	above).		
7.	Conclusions		I	have	presented	a	range	of	examples	of	research	on	cancer	as	a	way	to	make	clear	how	complex	the	control	processes	operating	on	mechanisms	in	living	cells	are.	The	hallmarks	of	cancer	identified	by	Hanahan	and	Weinberg	all	involve	altered	deployments	of	primary	mechanisms	that	figure	in	normal	cell	life.	Altered	deployment	results	from	changes	in	control	mechanisms	that	determine	when	these	various	primary	mechanisms	operate.	These	control	mechanisms	are	productively	analyzed	in	terms	of	pathways	consisting	of	components	that	act	sequentially	on	each	other.	But,	as	I	have	tried	to	illustrate,	these	pathways	often	interact	with	one	another,	constituting	networks.	In	addition	to	the	primary	mechanisms	that	are	responsible	for	phenomena	such	as	energy	procurement	and	protein	synthesis,	cells	contain	complex	networks	of	control	mechanisms	that	operate	on	flexible	constraints	in	the	primary	mechanisms.	Changes	in	control	mechanisms	result	in	the	redeployment	of	the	primary	mechanisms	to	maintain	the	altered	life	of	a	cancer	cell.			Philosophical	accounts	of	biological	mechanisms	have	not	emphasized	control,	instead	treating	mechanisms	as	operating	whenever	their	start-up	conditions	are	realized	(Machamer,	Darden,	and	Craver	2000).	In	this	paper	I	have	advanced	a	perspective	in	which	the	parts	and	operations	of	mechanisms	provide	constraints	that	direct	the	flow	of	free	energy,	enabling	the	mechanism	to	perform	work.	Many	of	the	constraints	in	mechanisms	are	flexible,	capable	of	being	altered	through	work	performed	by	other	mechanisms.	These	other	mechanisms	exercise	control.	They	too	involve	flexible	constraints	that	are	capable	of	being	operated	on	by	yet	other	mechanisms.	In	human-built	machines,	such	a	hierarchy	of	control	mechanisms	typically	tops	out	when	human	agents	alter	constraints	to	exercise	control.	But	in	biological	organisms	control	processes	originate	within	organisms	and	enable	the	primary	mechanisms	they	control	to	operate	appropriately	to	maintain	the	organisms.	Since	these	control	mechanisms	are	interconnected,	it	is	helpful	to	represent	them	in	a	network,	not	a	strict	hierarchy.		
	A	fundamental	lesson	to	be	learned	from	cancer	research	is	that	there	is	a	complex	web	of	control	operative	on	biological	mechanisms.	The	philosophical	analysis	of	mechanisms	needs	to	be	extended	from	focusing	exclusively	on	how	primary	mechanisms	produce	the	phenomenon	for	which	they	are	responsible	to	how	they	are	controlled.	This	involves	identifying	flexible	constraints	and	then	looking	beyond	the	primary	mechanisms	to	the	other	mechanisms	that	operate	on	those	constraints.	This	presents	a	challenging	new	task	for	those	interested	in	mechanistic	explanations	in	biology:	characterizing	how	control	networks	are	organized	in	a	manner	that	primary	mechanisms	produce	their	phenomena	in	ways	appropriate	to	maintaining	an	organism.			
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